Skip to main content
>_GENOSTRIDE

Scientific Methodology

Our framework for evaluating genetic research and lifestyle implications.

// The Gene-to-Action Framework

Genostride applies a rigorous, uniform classification scheme called the Gene-to-Action Framework to evaluate health-related genetic association studies. This system ensures every claims block is grounded in peer-reviewed science.

1. Evidence Strength

We categorize scientific evidence according to cohort sizes, clinical trial replication, and mechanistic plausibility:

  • Strong: Backed by multiple large, peer-reviewed human cohorts or meta-analyses, and featuring a clearly mapped biochemical pathway (e.g. CYP1A2 for caffeine clearance, LCT for lactase persistence).
  • Moderate: Good evidence in human cohorts; effect size is minor or strongly modulated by environmental variables (e.g. ACTN3 for fiber efficiency).
  • Limited / Mixed: Discrepancies exist between different cohort studies, or research is based on small pilot populations that have not been widely replicated.
  • Emerging: Primary research is highly recent or based largely on pre-clinical models (in vitro or animal models) without extensive human translation.

2. Expected Effect Size

We define how much a specific genetic variant contributes to a trait compared to lifestyle choices:

  • Potentially Meaningful: High contribution (e.g., LCT determining adult lactose non-persistence, which can dictate complete dietary tolerance).
  • Moderate: The variant has a noticeable, measurable impact on physiology but acts in tandem with lifestyle variables (e.g., CYP1A2 slowing caffeine clearance).
  • Small: The variation has a minute, statistical contribution to the trait (e.g., FTO variant slightly delaying satiety, which is easily overcome by dietary fiber adjustments).

3. Lifestyle Actionability

Can the reader reasonably adjust their lifestyle based on this information? We categorize actionability as:

  • High: Straightforward, low-risk changes with high likelihood of benefit (e.g., establishing a 10-hour caffeine curfew for slow metabolizers).
  • Moderate: Guides general splits or routines, but adjustments require progressive monitoring (e.g., training splits for ACTN3).
  • Low / Not currently actionable: Information is explanatory but does not guide clinical or daily interventions.